Home / Current Issue / Paper 1722610
API and Drug Master File Quality as Key Enablers of Pharmaceutical Manufacturing Localization in Saudi Arabia
Subject area: Science,Engineering and Technology · Area of research: Pharmaceutical Quality Management
Abstract
The extent to which Saudi Arabia's programme for localising its pharmaceutical industry relies on whether local manufacturers are able to obtain, comprehend, transfer, and consistently sustain control over high-quality active pharmaceutical ingredients (APIs) and the chemistry, manufacturing, and controls knowledge contained in Drug Master Files (DMFs) is examined in this review. Rather than viewing API quality and DMF quality as separate regulatory documents, the review treats them as linked industrial capabilities. It brings together recent work on pharmaceutical localisation, supply-chain resilience, Quality by Design, Process Analytical Technology, continuous manufacturing, and impurity control with the requirements of the Saudi Food and Drug Authority and the international ICH, FDA, EMA, and EDQM guidelines. The analysis states that localisation is successful when an API is not only in compliance with pharmacopeial standards at the time of release but is also backed by a reproducible process, scientifically justified specifications, qualified analytical methods, traceable impurity control, stability data, lifecycle change governance, and a current DMF that can be used to support regulatory assessments and technology transfer. In the context of Saudi Arabia, such attributes can help reduce uncertainty associated with technical transfers, shorten investigation periods, improve supplier qualification, strengthen local release testing, and enable effective post-approval change management. Two conceptual models are presented: an API-to-localisation value chain and a dual-engine readiness matrix that connects material quality with DMF maturity. The review concludes that policy on localisation should assess manufacturing readiness in terms of the depth of the quality system and the ability to transfer knowledge, rather than simply on the physical location of the final dosage-form production. The key priority actions should be benchmarking of DMF quality, the development of API suppliers on a risk-based basis, building up local analytical expertise, establishing structured lifecycle governance, using digital CMC data, and introducing incentives to encourage greater upstream manufacturing competence.
How to cite this paper
@article{1722610,
author = {Naseer Mitaigiri},
title = {API and Drug Master File Quality as Key Enablers of Pharmaceutical Manufacturing Localization in Saudi Arabia},
journal = {Iconic Research And Engineering Journals},
year = {2026},
volume = {10},
number = {2},
pages = {3154-3166},
issn = {2456-8880},
url = {https://www.irejournals.com/formatedpaper/1722610.pdf},
abstract = {The extent to which Saudi Arabia's programme for localising its pharmaceutical industry relies on whether local manufacturers are able to obtain, comprehend, transfer, and consistently sustain control over high-quality active pharmaceutical ingredients (APIs) and the chemistry, manufacturing, and controls knowledge contained in Drug Master Files (DMFs) is examined in this review. Rather than viewing API quality and DMF quality as separate regulatory documents, the review treats them as linked industrial capabilities. It brings together recent work on pharmaceutical localisation, supply-chain resilience, Quality by Design, Process Analytical Technology, continuous manufacturing, and impurity control with the requirements of the Saudi Food and Drug Authority and the international ICH, FDA, EMA, and EDQM guidelines. The analysis states that localisation is successful when an API is not only in compliance with pharmacopeial standards at the time of release but is also backed by a reproducible process, scientifically justified specifications, qualified analytical methods, traceable impurity control, stability data, lifecycle change governance, and a current DMF that can be used to support regulatory assessments and technology transfer. In the context of Saudi Arabia, such attributes can help reduce uncertainty associated with technical transfers, shorten investigation periods, improve supplier qualification, strengthen local release testing, and enable effective post-approval change management. Two conceptual models are presented: an API-to-localisation value chain and a dual-engine readiness matrix that connects material quality with DMF maturity. The review concludes that policy on localisation should assess manufacturing readiness in terms of the depth of the quality system and the ability to transfer knowledge, rather than simply on the physical location of the final dosage-form production. The key priority actions should be benchmarking of DMF quality, the development of API suppliers on a risk-based basis, building up local analytical expertise, establishing structured lifecycle governance, using digital CMC data, and introducing incentives to encourage greater upstream manufacturing competence.},
month = {August},
}